Benefix Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Benefix market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be attributed to factors such as the increased prevalence of hemophilia B, greater awareness of hemophilia management, improvements in treatment protocols, supportive healthcare policies, and higher healthcare expenditure.

Growth during the market's forecast period is expected to be driven by the rising prevalence of bleeding disorders, growing awareness of treatment options, expansion of healthcare infrastructure, increased health insurance coverage, and regulatory approvals for new therapies. Key trends in the forecast period include the integration of gene therapy, expanded home treatment options, a greater focus on patient-centric approaches, an increase in telemedicine for monitoring, and more collaborations between biotech companies.

The increasing prevalence of hemophilia is expected to drive the growth of the benefix market in the coming years. Hemophilia is an inherited disorder that affects blood clotting, causing excessive bleeding either from injury or spontaneously, which often requires medical intervention. The rise in hemophilia cases is attributed to genetic factors, greater recognition of acquired forms, and advancements in diagnostic techniques, leading to the identification of previously undiagnosed individuals. BeneFIX, a recombinant factor IX, is used to treat and prevent bleeding in hemophilia B, offering effective clotting through intravenous administration tailored to individual needs. For example, the World Federation of Hemophilia, a non-profit organization based in Canada, estimated in October 2023 that the prevalence of hemophilia A is approximately 17.1 per 100,000 males, and for hemophilia B, it’s 3.8 per 100,000. Severe cases are much rarer, with figures of 6 and 1.1 per 100,000 for hemophilia A and B, respectively. This results in an estimated 830,895 global patients, including 282,266 with severe forms and more than 257,146 identified cases, including 208,957 of hemophilia A and 42,203 of hemophilia B, along with over 100,000 cases of von Willebrand disease. Consequently, the increasing prevalence of hemophilia is driving the growth of the benefix market.

The growing attention to rare diseases is also to contribute to the expansion of the benefix market. Rare diseases are conditions that affect a small proportion of the population, typically fewer than 1 in 2,000 people. The growing focus on rare diseases is driven by advancements in medical research, better diagnostic tools, and enhanced patient advocacy, which have led to greater awareness and the development of specific treatments. BeneFIX provides an effective treatment for hemophilia B, a rare genetic bleeding disorder, helping improve care and management by offering a consistent clotting solution that reduces the need for frequent infusions and enhances quality of life. For example, the Personalized Medicine Coalition, a U.S.-based nonprofit, reported in February 2024 that the U.S. FDA approved 16 new personalized treatments for rare diseases in 2023, a significant rise from 6 in 2022. Thus, the increasing focus on rare diseases is boosting the benefix market.

Rising healthcare expenditure is key factor expected to drive growth in the benefix market. Healthcare expenditure refers to the total amount spent on health services and related activities during a given period, usually annually. The growth in healthcare spending is driven by an aging population, the prevalence of chronic diseases, rising service costs, increased demand, technological advancements, higher drug prices, the impact of COVID-19, medical inflation, and income disparities. The healthcare infrastructure supports the use of Benefix by ensuring proper storage, reconstitution, and administration by trained professionals, facilitating effective management of hemophilia B in both clinical and home settings. For example, according to a report from the National Library of Medicine in December 2023, U.S. healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, a faster rate than the 3.2% growth in 2021. Therefore, the rising healthcare expenditure is significantly driving the benefix market.

The key company operating in the benefix market is Pfizer Inc.

Asia-Pacific was the largest region in the benefix market in 2024 and it is expected to be the fastest-growing region in the forecast period. The regions covered in benefix report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the benefix market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Benefix is a recombinant coagulation factor IX product used to treat and manage bleeding disorders caused by factor IX deficiency, such as hemophilia B. It helps prevent and control bleeding episodes, manage perioperative bleeding, and reduce the frequency of spontaneous bleeding in hemophilia B patients through routine prophylaxis.

The main clinical indications for benefix are hemophilia B and surgical prophylaxis. Hemophilia B is a rare genetic bleeding disorder resulting from a deficiency of clotting factor IX, causing prolonged or spontaneous bleeding episodes. The primary users of Benefix include hospitals, clinics, and homecare settings. It is distributed through direct sales, retail pharmacies, and online pharmacies.

The benefix market research report is one of a series of new reports that provides benefix market statistics, including benefix industry global market size, regional shares, competitors with a benefix market share, detailed benefix market segments, market trends and opportunities, and any further data you may need to thrive in the benefix industry. This benefix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The benefix market consists of sales of products such as single-use vials, alprolix, beneFix+, and xyntha. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.